|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In summary, diffuse large B-cell lymphoma patients with either MYC/BCL6 rearrangements or MYC/BCL6 co-expression did not always have poorer prognosis; MYC expression levels should be evaluated simultaneously; and double-hit B-cell lymphoma needs to be refined based on the specific genetic abnormalities present in these tumors.
|
26573234 |
2016 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Taken together, our findings support a model in which c-MYC-driven transcriptional events, combined with epigenetic mechanisms, direct and regulate the expression of ABC genes with possible implications in tumor malignancy and drug efflux in CML.
|
21693596 |
2011 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The MYC protooncogene is a transcription factor whose overexpression is frequently associated with human neoplasia.
|
12909717 |
2003 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We show that a small-molecule inhibitor of eIF4A inhibits MYC expression and suppresses tumor growth in vivo.
|
25934076 |
2015 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
One possible reason is that the increased expression of the c-myc protein is not sufficient alone to promote proliferation and malignant transformation in these types of tumors.
|
9138112 |
1997 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Macrophage function and tumor-cell MYC expression may contribute to the PD-1-independent adverse prognostic effect of PD-L1<sup>+</sup> expression.
|
30666052 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Inhibition of BRD4 decreased bladder cancer cell proliferation concomitantly with the accumulation of cell apoptosis in vitro and suppressed tumor growth in vivo We further found that suppression of BRD4 decreased the mRNA and protein levels of EZH2, which was reversed by ectopic expression of C-MYC In particular, individual silencing of BRD4 using shRNA or the BET inhibitor JQ1 strikingly diminished the recruitment of C-MYC to EZH2 promoter in bladder cancer.
|
26939702 |
2016 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Isoxazole compound ML327 blocks MYC expression and tumor formation in neuroblastoma.
|
29207623 |
2017 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Sirtuin 6, a member of sirtuin family, is generally regarded as a tumor suppressor as it participates in suppressing hypoxia-inducible factor 1α and MYC transcription activity by deacetylating H3K9 (histone H3 lysine 9) and H3K56 (histone H3 lysine) at promoters of target genes, leading to the aerobic glycolysis inhibition and cell growth suppression.
|
28653878 |
2017 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
These findings establish MYC repression as a mechanism for ZFHX3's tumor suppressor activity and ZFHX3 as an indispensable factor for ERβ's tumor suppressor activity in prostate cancer cells.
|
30979864 |
2019 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Spearman's rank correlation coefficient analysis indicated that cytoplasmic C-MYC expression, Ki-67 index, age, WBC, as well as LDH level had significantly positive correlations with risk stratification (<i>P</i> = 0.000, 0.015, 0.000, 0.029 and 0.000, respectively), while CD8+TIL in tumor microenvironment negatively correlated with risk stratification of patients (<i>P</i> = 0.006).
|
28626618 |
2017 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Overall, there was weak positive correlation between ERG and MYC expression across all tumor nodules (rpb = 0.149, P = 0.045), although this correlation was strongest in secondary nodules (rpb = 0.520, P = 0.019).
|
27159573 |
2016 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In addition, in vivo experiments showed that miR-1827 inhibited tumor growth by reducing the levels of MYC and FAM83F.
|
31595558 |
2020 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
The Myc target gene JPO1/CDCA7 is frequently overexpressed in human tumors and has limited transforming activity in vivo.
|
15994934 |
2005 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
There appears to be a sharp threshold for MYC-induced T-cell lymphomagenesis because merely doubling the MYC level in a low-expressing line by breeding homozygous transgenic animals switched the phenotype from primarily monocytic tumors to exclusively T-cell tumors.
|
16537801 |
2006 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
A high frequency of C-MYC overexpression in endometrioid and clear cell carcinomas may suggest its role in the development of these tumor types.
|
12853350 |
2003 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
We identify MYC as a key regulator of the cellular stress responses and tumor cell viability as MYC expression was suppressed in drug-sensitive but not resistant cells.
|
28152508 |
2017 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Up-regulated GPX2 was related to a higher degree of tumor differentiation (P = 0.019). c-MYC was significantly over-expressed in specimens from male compared with female colon cancer patients (P = 0.012).
|
15734970 |
2005 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Deregulation of MYC can also induce apoptosis through activation of p53 and/or ARF tumor suppressors as a safeguard to prevent tumorigenesis.
|
28481271 |
2017 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
MYC protein expression was positively correlated with tumor proliferation rate (<i>r</i> = 0.37; <i>P</i> < 0.001) and negatively correlated with apoptotic count (<i>r</i> = -0.17; <i>P</i> < 0.001).
|
29141848 |
2018 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
A screening strategy restricting FISH testing to tumors of GCB subtype (by Lymph2Cx or Hans IHC) plus dual protein expression of MYC and BCL2 by IHC could limit testing to 11% to 14% of tumors, with a positive predictive value of 30% to 37%; however, this strategy would miss approximately one-quarter of tumors with HBGL-DH/TH with <i>BCL2</i> rearrangement and one-third of all HGBL-DH/TH.
|
29475959 |
2018 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
In this article, we investigate whether MEK/ERK inhibition, by the MEK/ERK inhibitor U0126, affects c-Myc protein level and growth of RMS tumor in an in vivo xenograft model.
|
19258428 |
2009 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
However, this mechanism was found to be inactive in all (10 of 10) tumor cell lines derived from a variety of tissues including those carrying normal and oncogenically activated c-myc genes.
|
2249657 |
1990 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
Tumor samples were assembled in a tissue microarray. c-myc gene dosage was correlated with clinicopathologic parameters, including the survival and gene expression of cyclooxygenases (COX-1 and COX-2) and proangiogenic growth factors (VEGF-A and VEGF-C).
|
16984727 |
2006 |
|
Neoplasms
|
0.500 |
AlteredExpression
|
group |
BEFREE |
C-MYC expression promoted high proliferation rates of MSC, attenuated but not abrogated their differentiation capacity, and did not immediately lead to tumor formation in the tested in vivo mouse model.
|
30836996 |
2019 |